Informatie:
Fout:
ID
23432
Beschrijving
Responsible Party: Torsten Liersch, Prof. Dr. med., University Medical Center Goettingen ClinicalTrials.gov Identifier: NCT03034473 History of Changes Other Study ID Numbers: TransValid-KFO179/GRCSG-A DRKS00003659 ( Registry Identifier: Deutsches Register Klinischer Studien ) UTN U1111-1131-9971 ( Registry Identifier: WHO Registry Network ) Study First Received: January 13, 2017 Last Updated: January 24, 2017 Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC-II-IV, With a 5-Fluorouracil-based Standard Radiochemotherapy Followed by Total Mesorectal Excision. (TransValid-A) ODM derived from: https://clinicaltrials.gov/ct2/show/NCT03034473
Link
https://clinicaltrials.gov/ct2/show/NCT03034473
Trefwoorden
Versies (1)
- 04-07-17 04-07-17 -
Geüploaded op
4 juli 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Rectal Cancer DRKS00003659 NCT03034473 DRKS00003659
Eligibility Rectal Cancer NCT03034473 DRKS00003659
- StudyEvent: ODM
Similar models
Eligibility Rectal Cancer NCT03034473 DRKS00003659
- StudyEvent: ODM
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Age
Item
Aged 18 to 85 years, inclusive
boolean
C0001779 (UMLS CUI [1])
Colorectal Cancer
Item
Histologically confirmed advanced primary rectal cancer localized up to 12 cm above the anocutaneous line (determined with a rigid rectoscope), classified as T3/T4 or N+ carcinomas or with evidence for synchronous, but resectable distant metastases (liver or lung metastases)
boolean
C0009402 (UMLS CUI [1])
Cancer Treatment
Item
No specific tumor treatment except colostomy due to tumor stenosis with ileus
boolean
C0920425 (UMLS CUI [1])
ECOG Performance Status
Item
World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) status ≤2
boolean
C1520224 (UMLS CUI [1])
Bone Marrow Function
Item
Adequate bone marrow function (WBC >3.0x10^9/L, neutrophils >1.5x10^9/L, thrombocytes >100x10^9/L, hemoglobin ≥10 g/dl)
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0031843 (UMLS CUI [1,2])
Liver Function
Item
Adequate liver function (bilirubin ≤2.0 mg/dl, SGOT, SGPT, AP, gamma-GT < three point five fold of upper level of normal range
boolean
C0232741 (UMLS CUI [1])
Serum Creatinine
Item
Serum creatinine < 1.5 mg/dl
boolean
C0201976 (UMLS CUI [1])
Informed Consent
Item
Written and signed informed consent indicating the understanding of the investigational nature and the study protocol.
boolean
C0021430 (UMLS CUI [1])
Control Group
Item
boolean
C0009932 (UMLS CUI [1])
Gynaecological Status
Item
Pregnant or lactating women
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Contraceptive Methods
Item
Men and women unwilling or unable to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment
boolean
C0700589 (UMLS CUI [1])
Substance Use Disorder
Item
Prolonged drug, medication or alcohol abuse
boolean
C0038586 (UMLS CUI [1])
Prior Chemotherapy
Item
Previous chemotherapy (up to 2 years before diagnosis of rectal cancer)
boolean
C1514457 (UMLS CUI [1])
Prior Radiotherapy
Item
Previous radiotherapy to the pelvic area
boolean
C0279134 (UMLS CUI [1])
Concurrent therapy
Item
Simultaneous therapy with other anti-cancer drugs
boolean
C0009429 (UMLS CUI [1])
Study Participation Status
Item
Participation in a clinical trial in the period 30 days prior to inclusion
boolean
C2348568 (UMLS CUI [1])
Study Protocol
Item
Patients (man and woman) who are not able or willing to accept treatment and follow-up care according to trial protocol
boolean
C2348563 (UMLS CUI [1])
Neurological or Mental Disease
Item
Patients (man and woman) with uncontrolled, serious physical or mental diseases, e.g.: instable cardiac disease in spite of medical treatment, myocardial infarction during the last 3 months prior to start of trial participation: neurological or psychiatric dysfunction including dementia or seizure disorder
boolean
C0027765 (UMLS CUI [1])
C0004936 (UMLS CUI [2])
C0004936 (UMLS CUI [2])
Infection
Item
Patients (man and woman) with uncontrolled, serious physical or mental diseases, e.g.: instable cardiac disease in spite of medical treatment, myocardial infarction during the last 3 months prior to start of trial participation: Disseminated infection or sepsis
boolean
C0009450 (UMLS CUI [1])
Disseminated intravascular coagulopathy
Item
Patients (man and woman) with uncontrolled, serious physical or mental diseases, e.g.: instable cardiac disease in spite of medical treatment, myocardial infarction during the last 3 months prior to start of trial participation: Disseminated intravascular coagulopathy
boolean
C4062443 (UMLS CUI [1])
Neuropathy
Item
Patients (man and woman) with uncontrolled, serious physical or mental diseases, e.g.: instable cardiac disease in spite of medical treatment, myocardial infarction during the last 3 months prior to start of trial participation: Symptomatic neuropathy (NCI CTC ≥2)
boolean
C0442874 (UMLS CUI [1])
Secondary malignancy
Item
Patients with secondary malignancies except basal cell carcinoma of the skin or carcinoma in situ of the cervix, which have been successfully treated. (The inclusion of patients with other tumors that were successfully treated and no recurrence within the last 3-5 years should be discussed before registration in the trial)
boolean
C3266877 (UMLS CUI [1])
Chronic diarrhea
Item
Chronic diarrhea (>grade 1 according NCI CTCAE)
boolean
C0401151 (UMLS CUI [1])
Hypersensitivity to Platin-Derivates or Study Medication
Item
Allergic reaction to platin-derivates or study medication
boolean
C0020517 (UMLS CUI [1,1])
C0032207 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0304229 (UMLS CUI [2,2])
C0032207 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0304229 (UMLS CUI [2,2])
Sorivudine
Item
Simultaneous treatment with sorivudine and analogous
boolean
C0207628 (UMLS CUI [1])
Dihydropyrimidine dehydrogenase deficiency
Item
Known Dihydropyrimidine dehydrogenase deficiency
boolean
C1959620 (UMLS CUI [1])